Journal of human immunity

Nirmatrelvir/ritonavir may lower long COVID risk in people with weak immune systems

Updated

Abstract

Essence

Acute nirmatrelvir/ritonavir use was associated with lower long COVID risk in immunodeficient patients.

Evidence

A retrospective study examined post-acute sequelae of SARS-CoV-2 infection after acute nirmatrelvir/ritonavir use in immunodeficient patients.

Caveat

The abstract provides no sample size or effect estimate, and the retrospective design leaves the finding in need of clinical trial confirmation.

Simplified

Full Text

Acknowledgments

This study was supported by Massachusetts Life Sciences and from the National Institute on Minority Health and Health Disparities of the National Institutes of Health under Award 1R01MD017816-01 (Jocelyn R. Farmer, Mei-Sing Ong, and Karen M. Gilbert). Jocelyn R. Farmer was additionally supported by a faculty development award from the American Academy of Allergy Asthma & Immunology.

Author contributions: Karen M. Gilbert: conceptualization, formal analysis, methodology, visualization, and writing—original draft. Mostafa Aglan: writing—original draft. Aditi Jogdand: writing—original draft, review, and editing. Neha V. Khairnar: data curation, project administration, resources, software, and validation. Henry Ssemaganda: data curation and writing—original draft, review, and editing. Mei-Sing Ong: data curation, formal analysis, funding acquisition, investigation, methodology, resources, supervision, and writing—review and editing. Jocelyn R. Farmer: conceptualization, supervision, and writing—original draft, review, and editing.

Data availability

The data used for this study are not publicly available due to an effort to protect patient privacy. The data may be available to share by the corresponding author upon request, only as additionally permitted by an Institutional Review Board–approved data use agreement.

References

Associated Data

Data Availability Statement

The data used for this study are not publicly available due to an effort to protect patient privacy. The data may be available to share by the corresponding author upon request, only as additionally permitted by an Institutional Review Board–approved data use agreement.

Funding

Competing interests

Disclosures: J.R. Farmer reported grants from Pharming, grants from Bristol Myers Squibb, and personal fees from Pharming outside the submitted work. No other disclosures were reported.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free